グリコピロニウム臭化物
Glycopyrrolate
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
基本情報
- CAS
596-51-0- 標準SMILES
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]- InChIKey
VPNYRYCIDCJBOM-UHFFFAOYSA-M- 分子式
- C19H28BrNO3
- 平均分子量
- 398.3 g/mol
概要
Glycopyrronium bromide is a quaternary ammonium salt composed of 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium and bromide ions in a 1:1 ratio. It is a quaternary ammonium salt and an organic bromide salt.
名称と識別子
- 優先名称
- Glycopyrrolate
- IUPAC
- (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
- 現地名
- グリコピロニウム臭化物
- 英語名
- Glycopyrrolate
- 分子式
- C19H28BrNO3-
- 分子量
- 398.33
名称と別名
GLYCOPYRROLATE596-51-0glycopyrronium bromideRobinulNodaptonTarodylTarodynCuvposaRobanulGlycopyrronii bromidumBromuro de glicopirronioBromure de glycopyrronium
名称をさらに表示
3-(フェニルシクロペンチルヒドロキシアセトキシ)-1,1-ジメチルピロリジニウム·ブロミドタロジルタロジングリコピロニウムブロミドグリコピロニウム3-(ヒドロキシシクロペンチルフェニルアセトキシ)-1,1-ジメチルピロリジニウム3-(フェニルシクロペンチルヒドロキシアセトキシ)-1,1-ジメチルピロリジニウムロバヌル1,1-ジメチル-3-[(2-シクロペンチル-2-フェニル-2-ヒドロキシアセチル)オキシ]ピロリジン-1-イウムノダプトングリコピロラート臭化グリコピロニウムロビナール【副交感神経作用薬】3-(2-シクロペンチル-2-ヒドロキシ-2-フェニルアセトキシ)-1,1-ジメチルピロリジニウムブロミド臭化グリコピロラートグリコピロニウム臭化物グリコピロニウム臭化物 (JAN)3-(フェニルシクロペンチルヒドロキシアセトキシ)-1,1-ジメチルピロリジニウム・ブロミドシーブリGLYCOPYRRONIUMGLYCOPYROLATEGlycopyrronium impurity NGlycopyrrone bromideGlycopyrronium for peak identificationGlycopyrronium for peak identification CRSPyrrolidinium, 3-(cyclopentylhydroxyphenylacetyl)oxy-1,1-dimethyl-, bromideahr504NVA237
SeebriROBINUL FORTESeebri NeohalerAHR-5041,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelateNVA 237NVA-237Glycopyrrolate, erythro-
データベース識別子
- CAS
596-51-0- PubChem CID
- 11693
- DTXSID
DTXSID6023109- ChEMBL
CHEMBL1201027- ChEBI
CHEBI:90972- EC Number
- 209-887-0
物性
構造計算による物性補完中
- 極性表面積
- 46.5 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 4
- 回転可能結合数
- 5
- 重原子数
- 24
- 形式電荷
- 0
- 複雑度
- 424
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Adjuvants, Anesthesia; Bronchodilator Agents; Muscarinic Antagonists; Parasympatholytics
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
Animal DrugsActive Ingredients (Glycopyrrolate) -> FDA Greenbook
Collision Cross Section203.8 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
物理化学的性質
- 融点
- 192 · 192-195°C
- 比重(密度)
- 1.3222 · 1.3222 (rough estimate)
- 屈折率
- 1.62 · 1.6200 (estimate)
- 貯蔵温度
- 2 · 2-8°C
- 溶解性
- 2 O: · H2O: ≥24mg/mL
- 外見
- 粉
- 色
- 白から黄褐色
- 水溶解度
- 2 O: · H2O: ≥24mg/mL
- Merck
- 14 · 14,4501
- 安定性
- Hygroscopic
- InChI
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
GHS分類
GHS Classification
Warning
H302 (23.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 51 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Regulatory InformationGlycopyrronium bromide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (23.5%)
毒性情報
HepatotoxicityLike other anticholinergic agents, glycopyrrolate has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. A major reason for its safety may relate to the low daily dose.
Adverse Effects
Potential adverse reactions associated with glycopyrrolate administration include anticholinergic symptoms such as mydriasis, hyperthermia, tachycardia, and cardiac arrhythmia. They may also include blurred vision, constipation, cycloplegia, dry mouth, dry skin, flushing, photophobia, urinary retention, and xerophthalmia.
Toxicity Summary
化学と産業
薬理情報
ATC Code
A03AB02
R - Respiratory system
A - Alimentary tract and metabolism
QR - Respiratory system
FDA Pharmacological Classification
GLYCOPYRROLATE
Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Muscarinic Antagonists [MoA]; Cholinergic Antagonists [MoA]; Anticholinergic [EPC]
GLYCOPYRROLATE ORAL SOLUTION
Cholinergic Muscarinic Antagonists [MoA]; Cholinergic Muscarinic Antagonist [EPC]; Cholinergic Antagonists [MoA]; Anticholinergic [EPC]
MeSH Pharmacological Classification
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
用途と製造
Use ClassificationAnimal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients
応用分野
説明Glycopyrrolate is an antagonist of muscarinic acetylcholine receptors (mAChRs; Kis = 0.42, 1.77, 0.52, 0.78, and 1.29 nM for the M1-M5 receptors, respectively). It induces relaxation of precontracted isolated human bronchi when used at concentrations of 0.01, 0.1, or 1 μM. Glycopyrrolate reduces post-prandial gastric antral motility in dogs when administered at a dose of 0.01 mg/kg. It inhibits salivation in a rat model of sialorrhea induced by pilocarpine with an ED50 value of 0.74 μg/kg. Formulations containing glycopyrrolate have been used in the treatment of sialorrhea, peptic ulcers, and chronic obstructive pulmonary disease (COPD).
関連反応
5 件
化合物ノート
読み込み中…